In this document, coronary angiogra- phy is understood to refer to invasive coronary angiography. 1.1. Methodology and Evidence Review Late-breaking clinical trials presented at the 2012 scien- tific meetings of the ACC, AHA, and European Society of Cardiology, as well as other selected data reported through October, 2013, were reviewed by the 2012 stable ischemic heart disease (SIHD) guideline writing committee along with the Task Force and other experts to identify trials and other key data that might affect guideline recommendations. On the basis of the criteria and considerations noted previously (see Preamble), recently published trial data and other clini- cal information were considered important enough to prompt a focused update of the 2012 SIHD guideline.4 Evidence considered for deliberation by the writing group was added to evidence tables in the Data Supplement available online, although it did not result in recommendation changes. Among the topics considered for inclusion in the focused update was the use of fractional flow reserve (FFR) for assessing interme- diate coronary lesions, including newer data from the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Although this was acknowledged to be an important new contribution to the literature, it did not alter the recommendations for FFR made in the 2012 full-text Consult the full-text version or the executive summary of the 2012 SIHD guideline for policy on clinical areas not cov- ered by the focused update.4,6 The individual recommenda- tions in this focused update will be incorporated into future revisions or updates of the full-text guideline. 1.2. 